Latest news with #Zoetis'
The Hindu
25-06-2025
- Business
- The Hindu
Infosys to offer U.S. animal health firm Zoetis agility, efficiency through digitisation
Infosys on Tuesday (June 24, 2025) announced a strategic collaboration with Zoetis, a global animal health company. Under this engagement, Infosys would enhance Zoetis' digital capabilities by integrating its AI solutions and automation services, it said in a statement. New Jersey-based Zoetis discovers, develops, manufactures and commercializes vaccines, medicines, diagnostics and other technologies for companion animals and livestock and has significant presence in India. Subhro Mallik, EVP and Global Head of Life Sciences, Infosys, said, for Zoetis, this transformative journey would reduce operational complexity and support long-term business objectives. 'This collaboration also underscores our commitment to delivering practical AI innovations and tailored digital solutions to the Life Sciences sector,'' he said. 'This collaboration with Infosys will help us improve operational efficiency as we deliver value to veterinarians, livestock producers, and pet owners globally. This represents our commitment to use digital innovation to continue to lead the animal health industry,' said Keith Sarbaugh, Executive Vice President and Chief Data and Technology Officer at Zoetis.
India Today
25-06-2025
- Business
- India Today
Stocks to watch on June 25: Infosys, Union Bank, RITES, Aurobindo Pharma
Stock market investors are expected to keep a close watch on several key companies during Tuesday's trade, after a volatile session on Tuesday as it tracked the developments in the Middle East. The benchmark indices showed sharp ups and downs before closing with small a detailed look at the stocks that may move today based on company announcements and market has announced a strategic partnership with Zoetis, the world's leading animal health company. The collaboration will help Zoetis improve its IT operations by using advanced artificial intelligence (AI) solutions and automation tools. The move is aimed at improving efficiency and supporting Zoetis' growth through better digital BANK OF INDIAThe government has cancelled the appointment of Pankaj Dwivedi as Executive Director of Union Bank. Dwivedi, who was earlier a general manager at Punjab & Sind Bank, was appointed in March 2023 for a three-year term. His removal may raise questions about management changes at the public sector GROUP INDIAPromoter Timex Group Luxury Watches BV, Netherlands, will sell up to 15% stake in Timex Group India through an Offer for Sale (OFS). The base offer is 7.5% or around 75.71 lakh shares. The OFS opens for non-retail investors on June 25 and for retail investors on June 26. The floor price has been set at Rs 175 per PHARMAAurobindo Pharma's subsidiary CuraTeQ Biologics has received approval from the UK's drug regulator MHRA for its biosimilar medicine, Dyrupeg. This drug is used to treat cancer patients suffering from neutropenia, a condition that lowers white blood cell count. The product had earlier received authorisation in the European Union in April is the third biosimilar from CuraTeQ to get approval from MHRA, after Bevqolva in December 2024 and Zefylti in May MOTORSTata Motors said that its production process has not yet been impacted by China's restrictions on exports of rare-earth magnets. These magnets are important for electric vehicles. The company is actively looking at other options for sourcing and developing new technologies to reduce dependency on has received a Letter of Intent worth Rs 28.5 crore from Gujarat Urban Development Company. The company will work as a third-party inspection agency for various water supply and sewage treatment projects in the state under Amrut 2.0 and other INDUSTRIESPTC Industries' subsidiary, Aerolloy Technologies, has signed a Memorandum of Understanding (MoU) with Safran Aircraft Engines. The deal is for producing parts and materials used in military aircraft engines. This move is likely to boost defence manufacturing under the 'Make in India' TECHNOLOGIESThe board of KFin Technologies has approved the re-appointment of Vishwanathan Mavila Nair as Non-Executive Director and Chairperson of the company. His second term will begin from October 1, 2025, and will last for one TECHNOLOGY INDIAKaynes Technology has raised Rs 1,600 crore by allotting 28.72 lakh shares to qualified institutional buyers at an issue price of Rs 5,569.50 per share. The fundraise was part of a Qualified Institutions Placement (QIP) that closed on June 24. Some of the investors include Motilal Oswal Mutual Fund, Nomura Funds, HSBC Mutual Fund, Kotak Mahindra AMC, and HDFC Life Insurance WELLNESSZydus Wellness' board has approved the voluntary closure of its subsidiary Naturell (India) Private Limited. The decision is part of a plan to simplify the company's structure and bring operational efficiency by merging Naturell with the main entity.- Ends advertisement
Business Upturn
24-06-2025
- Business
- Business Upturn
Infosys collaborates with Zoetis to boost digital capabilities
By Aman Shukla Published on June 24, 2025, 15:34 IST Infosys (NSE, BSE, NYSE: INFY), a global leader in digital services and consulting, has announced a long-term strategic collaboration with Zoetis, the world's top animal health company. The partnership aims to strengthen Zoetis' IT operations and digital capabilities through the use of cutting-edge artificial intelligence and automation solutions. This collaboration is set to enhance agility, reduce complexity, and help Zoetis adapt more efficiently to a dynamic business environment. Infosys will leverage its industry expertise to deliver AI-driven innovations that align with Zoetis' long-term goals, particularly in the evolving Life Sciences space. Subhro Mallik, EVP and Global Head of Life Sciences at Infosys, said, 'We are excited to collaborate with Zoetis on this transformative journey that will reduce operational complexity and support long-term business objectives. This collaboration also underscores our commitment to delivering practical AI innovations and tailored digital solutions to the Life Sciences sector.' Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Wire
05-06-2025
- Business
- Business Wire
Zoetis Releases 2024 Sustainability Progress Update
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis published its 2024 Sustainability Progress Update 'Advancing Sustainability in Animal Health for a Better Future' to highlight the company's continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis' fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and the Planet – that strengthen its business by creating long-term value, enhancing stakeholder trust, and supporting sustainable growth. 'Zoetis contributes to a healthier future for communities, animals and the planet thanks to our colleagues who demonstrate their commitment to the Driven to Care strategy and are empowered to advance our company's purpose,' said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. 'By embedding our sustainability strategy across our business, and through purposeful partnerships with our customers and other stakeholders, our actions address challenges at the intersection of people, animals and the environment.' Highlights of the company's progress in 2024 include: Communities – Care and Collaboration 20,404 hours of community-based volunteer time reported by colleagues, which represents 102% of the company's stated goal and a 23% increase from hours reported in 2023. Zoetis provides paid time off for colleagues to volunteer and support animals, their caregivers, and local communities. The Zoetis Foundation disbursed $11.3 million in grants in 2024 ($26.2 million since 2021), supporting education, well-being, and livelihoods for veterinarians and farmers as well as humanitarian aid and a matching gifts program. The grantmaking in 2024 included $3.5 million in funding that will provide nearly 500 veterinary student scholarships. $8.9 million invested in communities through Zoetis Inc. corporate giving; efforts included vet care access to approximately 322,000 pet owners in need and providing care to approximately 428,000 animals affected by disasters. 86% colleague engagement rate driven by a culture anchored in Core Beliefs; the company's focus on colleagues includes talent development programs, mentorship and coaching, and comprehensive benefits to foster an inclusive workplace where every colleague can thrive. Animals – Innovation in Animal Health Launched a strategic partnership with Danone, leveraging Zoetis' genetics expertise to advance the dairy industry's approach to breeding cattle for sustainability. Also, began a research collaboration with AgNext to close data gaps and meet the evolving sustainability needs of the cattle industry. Introduced solutions for Highly Pathogenic Avian Influenza (HPAI) including existing vaccines used to help protect California Condors in the U.S. and trialed on five species of endangered birds in New Zealand. Treated 16.7 million cows and 354.9 million chickens in Sub-Saharan Africa, exceeding goals, through the company's African Livestock Productivity and Health Advancement (A.L.P.H.A. Plus) initiative. Planet – The Drive to Protect our Planet Continued progress toward carbon neutrality in the company's own operations, reducing total Scope 1 and 2 emissions by 26.7% from 2023. This reduction was primarily driven by increased renewable energy credits procured through a virtual power purchase agreement. 80.6% of the company's global electricity is from renewable sources. The company's locations covered by renewable electricity include 15 manufacturing sites, its R&D headquarters in Kalamazoo, Michigan, and its international headquarters office in Dublin, Ireland. Installed an 800kW solar array at the Rutherford manufacturing site in Australia – making it Zoetis' eighth location to generate a portion of its power through on-site solar energy. Implemented new sustainable packaging solutions and reduced waste through recycled paper packaging for a cattle vaccine in Europe and replaced single use with reusable pallets and transitioned from air to sea freight in Spain. For more detailed disclosures on the company's sustainability programs, practices and policies, please download Zoetis' 2024 Sustainability Progress Update or visit Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care aspirations, and report annually. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit DISCLOSURE NOTICES Forward-Looking Statements: This press release and the 2024 Sustainability Progress Update (including the 2024 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned 'Forward-Looking Statements and Factors That May Affect Future Results' and 'Item 1A. Risk Factors,' in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at or on request from Zoetis. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. See the footnotes within our 2024 Sustainability Progress Update for more details regarding all calculations.
Yahoo
23-05-2025
- Business
- Yahoo
2 Dividend Stocks to Buy With $500 and Hold Forever
Zoetis is a leading animal health company with a deep lineup and significant long-term tailwinds. Abbott Labs has a diversified portfolio of medical devices and several attractive growth avenues. Both healthcare stocks have impeccable dividend track records and bright futures still ahead. 10 stocks we like better than Zoetis › Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest. However, times like these might help remind us that some corporations are more resilient than others. Among the most resilient are longtime dividend payers with excellent underlying businesses and strong outlooks. That description fits Zoetis (NYSE: ZTS) and Abbott Laboratories (NYSE: ABT), two giants in the healthcare sector. For those with $500 to spare (not being saved for emergencies) and in the market for income stocks to park in their portfolios, here's why these two companies are outstanding candidates to put that money into now. Zoetis is a leading animal health company. The company's portfolio of products is deep and diversified. It markets medicines for companion animals, livestock, fish, poultry, and more. Zoetis has over 300 product lines and about 15 that generate over $100 million in annual revenue. Despite its usually strong performance, Zoetis has encountered some issues in the past year. The company's guidance for its fiscal 2025 was weak, or at least so the market thought. Furthermore, Zoetis will face increased competition for one of its growth drivers. The company's Apoquel, which helps relieve allergic itch in dogs, has been a top performer, but one of Zoetis' rivals, Elanco Animal Health, launched an alternative last year. While competition has been, and will continue to be, one of Zoetis' threats, the animal health specialist has been successful despite that. It routinely grows its revenue at a faster rate than the industry average. It is the leader, or one of the market leaders, across most categories and regions where it operates. The company also has important long-term growth drivers. Zoetis' companion animal segment generates the most revenue and is the most promising. Younger generations (millennials and Gen Z) have fewer kids than previous generations but are increasingly humanizing pets. Some of the spending which, for older folks, would have gone into caring for children will be redirected toward cats and dogs due to this dynamic. That should benefit Zoetis, which continues to develop and market newer and better pet care products. That's just one long-term tailwind. Here's another. A growing world population will lead to an increased demand for animal protein. To provide that in spades, we need to care for livestock, something else Zoetis specializes in. The company might encounter issues in the short run due to marketwide troubles and mounting competition, but Zoetis' long-term prospects look attractive thanks to its impressive track record in the industry and its existing lineup of products. Lastly, Zoetis is a terrific dividend stock, even with a mediocre forward yield of 1.2% -- the S&P 500's average is 1.3%. Zoetis has increased its payouts by 502% in the past decade while still boasting a conservative cash payout ratio of 34.2%. The stock should consistently deliver more dividend growth and solid returns to investors holding on to it for good. Abbott Laboratories is best known for its work in the medical device market. Sure enough, this segment is home to its most attractive sources of revenue and biggest growth drivers, but one of the company's strengths is its diversification. Abbott is also a leader in nutrition, boasts a solid diagnostic segment, and markets various pharmaceutical products. Abbott Laboratories has succeeded in keeping its business afloat even when significant problems in one segment or another arise, thanks to its reliance on multiple sources of revenue. That's why it routinely generates consistent revenue and earnings. Meanwhile, the company's prospects look strong. One of the company's key growth drivers is its FreeStyle Libre franchise, a family of continuous glucose monitoring (CGM) systems. The healthcare leader has to contend with stiff competition from DexCom in this area, but despite this long-standing challenge, the FreeStyle Libre has become the most successful medical device ever in terms of dollar sales -- and there is still ample room for growth, considering that the worldwide CGM diabetes market remains underpenetrated. Elsewhere, several other product lines and segments should see increased demand over the long run due to an aging worldwide population. Consider Abbott's MitraClip, a minimally invasive option to treat a serious heart problem called mitral valve regurgitation. This issue is more common among people aged 65 and older. That's why demand for the MitraClip (or other products like it that Abbott manufactures) will grow as people aged 65 and up make up a larger percentage of the population. It might not make a massive difference for just one of these products, but higher demand across the range of the company's portfolio will meaningfully affect its results. Turning to Abbott's income profile, the company has raised its payouts for 53 consecutive years, making it a Dividend King. The stock might only offer a yield of 1.8%, but its cash payout ratio looks reasonable at 60.4%. Abbott will encounter some issues. It is facing lawsuits over its infant formula products for premature babies allegedly causing fatal illnesses, among others. It will also have to deal with a competitive landscape and, potentially, the continuing threat of tariffs that could increase its costs and squeeze its bottom line. However, Abbott's strong presence in the healthcare industry, solid underlying business, and innovative capabilities should allow it to continue performing well over the long run, despite the headwinds. It's an excellent buy-and-hold forever stock for income seekers. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $644,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $807,814!* Now, it's worth noting Stock Advisor's total average return is 962% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Zoetis. The Motley Fool recommends DexCom and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Dividend Stocks to Buy With $500 and Hold Forever was originally published by The Motley Fool
